摘要
目的监测医院重症监护病房患者感染阴沟肠杆菌产AmpC酶和超广谱β-内酰胺酶(ESBLs)的耐药性特征。方法采用酶提取物三维试验方法检测AmpC酶和检测ESBLs。结果 86株阴沟肠杆菌中检出单产ESBLs 21株、单产AmpC酶20株、同时产AmpC酶和ESBLs株即SSBL阳性株15株,检出率分别为24.4%、23.3%和17.4%;产酶阴沟肠杆菌对抗菌药物的耐药率大部分均高于既非产Ampc酶又非产ESBLs菌株,即SSBL(-)。结论重症监护病房产AmpC酶和ESBLs的阴沟肠杆菌呈多药耐药,对于产AmpC酶阴沟肠杆菌临床经验用药应首选头孢四代抗菌药物,对于产ESBLs酶阴沟肠杆菌临床经验用药,应首选碳青霉烯类抗菌药物。
OBJECTIVE To study the drug resistance characteristics of extended-spectrum β-lactamases and AmpC β-lactamase produced by Enterobacter cloacae in intensive care units.METHODS The three dimensional testing was used to detect the AmpC β-lactamase and ESBLs.RESULTS Of the 86 E.cloacae strains,ESBLs was detected in 21 strains,AmpC was detected in 20 strains,the AmpC and ESBLs,also the SSBL,was detected in 15 strains,the detection rates were 24.4%,23.3% and 17.4%,respectively.The drug resistant rate of enzyme-producing E.cloacae to most of antibiotics was higher than that of SSBL（-）.CONCLUSION AmpC β-lactamase and ESBLs-producing E.cloacaes in intensive care units is multidrug-resistant,for the serious infection induced by E.cloacae producing AmpC β-lactamase,ciprofloxacin is the first choice for the treatment.For the serious infection induced by E.cloacae producing ESBLs,carbapenem is first choice for the treatment.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2011年第12期2620-2621,共2页
Chinese Journal of Nosocomiology
